Post Market ATS 3f® Aortic Bioprosthesis, Model 1000, Size 19mm

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

WITHDRAWN

Study Classification

OBSERVATIONAL

Study Start Date

2010-06-30

Study Completion Date

2011-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to evaluate the safety and efficacy of the ATS 3f® Aortic Bioprosthesis, Model 1000 (Equine Pericardial Bioprothesis) size 19mm in a patient population undergoing isolated aortic valve replacement of his/her native aortic valve, or replacement of a failed prosthesis.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

ATS 3f(r) Aortic Bioprosthesis Model 1000 Post Approval Study

NCT01116037

Heart Valve Diseases

TERMINATED NA

ATS 3f Enable(tm) Aortic Bioprosthesis, Model 6000

NCT01116024

Heart Valve Diseases

COMPLETED NA

ProspeCtive, nOn-randoMized, MulticENter Clinical Evaluation of Edwards Pericardial Bioprostheses With a New Tissue Treatment Platform (COMMENCE)

NCT01757665

Aortic Stenosis Mitral Stenosis Aortic Valve Insufficiency +2 more

ACTIVE_NOT_RECRUITING NA

Clinical Evaluation of Percutaneous Implantation of the Medtronic CoreValve Aortic Valve Prosthesis (18Fr-Study)

NCT01051518

Aortic Valve Stenosis

COMPLETED NA

Percutaneous Aortic Valve 18F System for the Treatment of Patients With Severe Aortic Stenosis

NCT01475799

Aortic Valve Stenosis

UNKNOWN NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

A multi-center, post market, non-randomized trial, designed to obtain safety and efficacy data from patients implanted with the size 19mm Model 1000 heart valve. Each enrolled patient will be followed until one year post-implantation. Data will be collected both retrospectively and prospectively, on patients who were implanted from 1-Jan-2009 to 31-Dec-2009 with the 19mm Model 1000. The data collected will be pooled with the data currently collected, under the U.S. Food and Drug Administration (FDA) IDE Number G01284 for submission to the U.S. FDA.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Heart Valve Diseases

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Replacement aortic heart valve

ATS 3f® Aortic Bioprosthesis, Model 1000, Size 19mm

ATS Medical 3f® Aortic Bioprosthesis, Model 1000 19mm

Intervention Type DEVICE

Replacement aortic heart valve

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

ATS Medical 3f® Aortic Bioprosthesis, Model 1000 19mm

Replacement aortic heart valve

Intervention Type DEVICE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Model 1000, 19mm

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* The patient required isolated aortic valve replacement with or without concomitant procedures such as coronary artery bypass or another valve reconstruction with an ATS 3f® Aortic Bioprosthesis Model 1000 (size 19mm) between the dates of 1-Jan-2009 and 31-Dec-2009. The three remaining heart valves must be of native tissue.
* The patient is geographically stable and willing to return to the implant center for any required follow-up visits.
* The patient has been adequately informed and consents to his/her participation in the clinical study, and of what will be required of him/her, in order to comply with the protocol.

Exclusion Criteria

* The patient is twenty (20) or less than twenty years of age.
* The patient is an intravenous drug and/or alcohol abuser.
* The patient presented for implant with active endocarditis.
* The patient presented for implant with congenital bicuspid aortic anatomy.
* The patient had a previously implanted prosthetic valve that was not replaced by the study valve.
* The patient required mitral, tricuspid or pulmonic valve replacement.

Minimum Eligible Age

21 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No